Whereas currently available biomarkers such as PD-L1 expression and tumour mutation burden are useful for identifying a subset of patients likely to benefit from immune checkpoint inhibitors, early recognition and treatment of sarcopenia have the potential to bring additional benefits to all patients scheduled to receive immune checkpoint inhibitors. Here, CD274 is linked to sarcopenia.